Cardiovascular Systems Inc (NASDAQ:CSII) – Research analysts at William Blair issued their Q4 2019 earnings estimates for shares of Cardiovascular Systems in a research note issued to investors on Wednesday. William Blair analyst M. Kaczor expects that the medical device company will post earnings per share of $0.05 for the quarter. William Blair has a “Market Perform” rating on the stock.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a report on Friday. ValuEngine lowered shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. BidaskClub upgraded shares of Cardiovascular Systems from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective (down previously from $37.00) on shares of Cardiovascular Systems in a report on Thursday, October 26th. Finally, Leerink Swann decreased their price objective on shares of Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday. Three research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $27.00.
Cardiovascular Systems (NASDAQ:CSII) last released its earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The firm had revenue of $52.63 million during the quarter, compared to analyst estimates of $53.39 million. Cardiovascular Systems had a negative net margin of 1.62% and a negative return on equity of 0.51%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business earned $0.03 EPS.
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlueCrest Capital Management Ltd purchased a new position in Cardiovascular Systems during the 2nd quarter valued at about $204,000. Advisor Group Inc. increased its position in Cardiovascular Systems by 0.4% during the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock valued at $263,000 after purchasing an additional 35 shares during the period. JPMorgan Chase & Co. increased its position in Cardiovascular Systems by 34.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock valued at $265,000 after purchasing an additional 2,115 shares during the period. UBS Asset Management Americas Inc. increased its position in Cardiovascular Systems by 9.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 9,193 shares of the medical device company’s stock valued at $296,000 after purchasing an additional 800 shares during the period. Finally, Trexquant Investment LP purchased a new position in Cardiovascular Systems during the 3rd quarter valued at about $276,000. 75.29% of the stock is currently owned by institutional investors and hedge funds.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.